This high-risk group includes patients with high-grade papillary stage Ta or T1 tumors and any patient with carcinoma in situ (CIS), and makes up 15–44% of patients with non-muscle-invasive ...

Background and Aim: Intraductal papillary mucinous tumor (IPMT ... Although it has been reported that the branch duct type IPMT is less invasive than the main duct type IPMT, we experienced ...

Invasive lobular carcinoma (ILC) affects the lobules of the breast, which contain the glands that produce breast milk. It is a type of breast cancer, and the outlook can vary depending on multiple ...

75% of bladder cancer patients are diagnosed with Non-Muscle-Invasive Bladder Cancer (NMIBC), where: 90% have papillary disease (Ta or T1) (disease that penetrates the bladder lining, but does not ...

Ractigen’s small activating RNA (saRNA) therapy, RAG-01, designed to treat non-muscle invasive bladder cancer (NMIBC ... found that 66.7% of patients with papillary tumours remained disease ...

for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary ...